



# SHUKRA

## PHARMACEUTICALS LTD.

### Statement of Standalone Audited Financial Results for the Quarter Ended 31.12.2018

SR NO	PARTICULARS	Standalone (Rs. Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		31-12-2018 (unaudited)	30-09-2018 (Unaudited)	31-12-2017 (Unaudited)	31-12-2018 (unaudited)	31-12-2017 (unaudited)	31-03-2018 (Audited)
1	<b>Income</b>						
	Revenue from operations -						
	Other income	114.37	86.32	328.45	305.45	435.02	536.19
	<b>Total income</b>	0.10	0.17	1.67	3.73	6.61	11.15
2	<b>Expenses</b>	<b>114.47</b>	<b>86.49</b>	<b>330.12</b>	<b>309.18</b>	<b>441.63</b>	<b>547.34</b>
(a)	Cost of materials consumed						
(b)	Purchases of stock-in-trade	8.39	4.94	97.18	25.36	108.56	124.32
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade			(16.95)	(10.01)		
(d)	Employee benefit expense	0					
(e)	Finance costs	54.79	47.44	34.11	145.67	91.37	128.36
(f)	Depreciation, depletion and amortisation expense	0		0.59	0.02	0.78	4.56
(f)	Other Expenses	18.42	18.42	17.50	55.26	37.50	73.70
	<b>Total expenses</b>	28.64	7.67	59.96	60.11	47.95	121.79
3	<b>Total profit before exceptional items and tax</b>	<b>110.24</b>	<b>78.47</b>	<b>192.39</b>	<b>276.41</b>	<b>286.16</b>	<b>452.73</b>
4	Exceptional Items	4.23	8.02	137.73	32.77	155.47	94.61
5	<b>Total profit before tax</b>	<b>4.23</b>	<b>8.02</b>	<b>137.73</b>	<b>5.17</b>		
7	<b>Tax expense</b>				<b>27.65</b>	<b>155.47</b>	<b>94.61</b>
8	Current tax						
9	Deferred tax	1.06	1.55	41.32	7.36	46.64	17.03
10	<b>Total tax expenses</b>	<b>3.10</b>	<b>5.82</b>		<b>15.11</b>		<b>(24.75)</b>
11	<b>Total profit after tax</b>	<b>4.16</b>	<b>7.37</b>	<b>41.32</b>	<b>22.47</b>	<b>46.64</b>	<b>(7.72)</b>
	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement						
14	<b>Net Profit Loss for the period from continuing operations</b>	<b>0.07</b>	<b>0.66</b>	<b>96.41</b>	<b>5.18</b>	<b>108.83</b>	<b>102.33</b>
15	Profit (loss) from discontinued operations before tax						
16	Tax expense of discontinued operations						
17	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0.07</b>	<b>0.66</b>	<b>96.41</b>	<b>5.18</b>	<b>108.83</b>	<b>102.33</b>
18	Share of profit (loss) of associates and joint ventures accounted for using equity method						
19	<b>Total profit (loss) for period</b>	<b>0.07</b>	<b>0.66</b>	<b>96.41</b>	<b>5.18</b>	<b>108.83</b>	<b>102.33</b>
20	Other comprehensive income net of taxes						
21	<b>Total Comprehensive Income for the period</b>	<b>0.07</b>	<b>0.66</b>	<b>96.41</b>	<b>5.18</b>	<b>108.83</b>	<b>102.33</b>
22	<b>Total profit or loss, attributable to</b>	<b>0.07</b>	<b>0.66</b>	<b>96.41</b>	<b>5.18</b>	<b>108.83</b>	<b>102.33</b>
	Profit or loss, attributable to owners of parent						
	Total profit or loss, attributable to non-controlling interests						
23	<b>Total Comprehensive income for the period attributable to</b>						
	Comprehensive income for the period attributable to owners of parent						
	Total comprehensive income for the period attributable to owners of parent non-controlling interests						
24	<b>Details of equity share capital</b>						
	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57	156.57
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
25	<b>Details of debt securities</b>						
	Paid-up debt capital						
	Face value of debt securities						
26	Reserves excluding revaluation reserve	1,388.07	1,381.94	1,372.06	1,388.07	1,372.06	1,366.52
27	<b>Earnings per share</b>	<b>0.00</b>	<b>0.04</b>	<b>6.16</b>	<b>0.33</b>	<b>6.95</b>	<b>0.65</b>
i	<b>Earnings per equity share for continuing operations</b>						
	Basic earnings (loss) per share from continuing operations	0.00	0.01	6.16	0.33	6.95	0.65
	Diluted earnings (loss) per share from continuing operations	0.00	0.01	6.16	0.33	6.95	0.65
ii	<b>Earnings per equity share for discontinued operations</b>						
	Basic earnings (loss) per share from discontinued operations						
	Diluted earnings (loss) per share from discontinued operations						
ii	<b>Earnings per equity share</b>						
	Basic earnings (loss) per share from continuing and discontinued operations						
	Diluted earnings (loss) per share from continuing and discontinued operations						
28	Debt equity ratio						
29	Debt service coverage ratio						
30	Interest service coverage ratio						
31	Disclosure of notes on financial results						

#### NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 13th February 2019. The statutory auditors have carried out a limited review of the results for the quarter ended 31st December, 2018 and have expressed an unqualified audit opinion.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind As), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. Beginning April 1, 2017 Company has for the first time adopted Ind As with transition date of April 1, 2016
- The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015.
- The Company is operating in single segment, so above results are for single segment only.

Date: 13.02.2019

Place: Ahmedabad

For and on behalf of the Board of Directors

Dakshesh Shah - Director  
DIN : 0361666



CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721,Gujarat, India. Ph.: 02764-286317